QUOTE AND NEWS
Motley Fool  Jul 19  Comment 
A long-awaited mega-merger is announced, Exelixis reminds Wall Street that its pipeline is more than a single compound, and Amgen shows flashes of what's coming down its pipeline.
DailyFinance  Jul 17  Comment 
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Pharming Group NV ( EURONEXT: PHARM) today announced that the Food and Drug Administration has approved RUCONEST® (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg for the treatment...
Motley Fool  Jul 16  Comment 
Why aren't investors celebrating Salix Pharmaceuticals's acquisition of Cosmo, and should they be?
DailyFinance  Jul 15  Comment 
Levi & Korsinsky is investigating the Board of Directors of Salix Pharmaceuticals, Ltd. (“Salix” or “the Company”) (Nasdaq: SLXP) for possible breaches of fiduciary duty and other violations of state law in connection...
Motley Fool  Jul 14  Comment 
Expanded labeling for the sub-q form of Relistor could add $100 million in revenue, but doesn't change the business to a large extent
Benzinga  Jul 14  Comment 
Exelixis (NASDAQ: EXEL) shares gained 12.78% to $3.75 in pre-market trading after the company reported that coBRIM has met primary endpoint in phase 3 trial. Progenics Pharmaceuticals (NASDAQ: PGNX) shares surged 11.08% to $4.71 in pre-market...
newratings.com  Jul 14  Comment 
WASHINGTON (dpa-AFX) - Salix Pharmaceuticals Ltd. (SLXP) and Progenics Pharmaceuticals (PGNX) announced that the Food and Drug Administration has informed Salix that RELISTOR (methylnaltrexone bromide) Subcutaneous Injection, 20 mg/ml, for the...
StreetInsider.com  Jul 14  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Progenics+Pharma+%28PGNX%29%2C+Salix+Pharma+%28SLXP%29+Receive+Response+from+FDA+on+RELISTOR+sNDA+as+OIC+Treatment/9656698.html for the full story.
TheStreet.com  Jul 10  Comment 
Story updated at 9:50 a.m. to reflect market activity. NEW YORK (TheStreet) -- UBS raised its price target for Salix Pharmaceuticals to $137 from $123 Thursday. Salix Pharmaceuticals fell -0.6% to $132.47 in morning trading. The firm...




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing, and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases. The company has a number of products currently approved for sales. These include Colazal (balsalazide disodium) for the treatment of mild to moderate active ulcerative colitis, Azasan (azathioprine) immuno-suppressive therapy for renal homo-transplant rejection and rheumatoid arthritis, and Anusol/Proctocort (hydrocortisone) for the relief of inflammatory dermatoses and hemorrhoids. In May 2004, the company received final Food and Drug Administration (FDA) approval for Xifaxan (rifaximin), an oral antibiotic for the treatment of traveler's diarrhea. Salix Pharmaceuticals is working on additional indications for Xifaxan, as well as a granulated formulation of mesalamine a common treatment option for ulcerative colitis.

Salix subsequently added new products to its portfolio including Visicol, indicated for colon cleansing prior to colonoscopy OsmoPrep, a next-generation Visicol which was launched in June 2006 and MoviPrep, a liquid bowel cleansing agent which was launched in October 2006. While Visicol and OsmoPrep were acquired by the company through its merger with InKine Pharmaceutical, exclusive U.S. in-licensing rights for MoviPrep were acquired from Norgine B.V. Recent additions to the product portfolio include Sanvar IR, indicated for the treatment of acute esophageal variceal bleeding (EVB) two hospital-based products, Pepcid Oral Suspension (indicated for several gastrointestinal indications including the treatment of duodenal ulcer, benign gastric ulcer and gastroesophageal reflux disease) and Diuril Oral Suspension (an adjunctive therapy in edema associated with several conditions including hepatic cirrhosis), from Merck and metoclopramide Zydis, indicated for short term (4 12 weeks) therapy for adults with symptomatic documented gastroesophageal reflux who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastric stasis.

Salix focuses primarily on the U.S. pharmaceutical market, promoting its drugs through its specialized sales force. Management also seeks to form strategic alliances to market its products outside the U.S. in order to avoid the significant costs, risks, and infrastructure inherent in assembling an international sales force. Salix is located in Morrisville, NC and employs roughly 240 professionals.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki